Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human retinal pigment epithelial cell therapy - Astellas Pharma

Drug Profile

Human retinal pigment epithelial cell therapy - Astellas Pharma

Alternative Names: ACT hESC-RPE; ASP-7317; hESC-derived RPE; hRPE cell therapy; Human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells - Astellas; MA09-hRPE

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advanced Cell Technology
  • Developer Astellas Institute for Regenerative Medicine; Astellas Pharma
  • Class Eye disorder therapies; Pluripotent stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Age-related macular degeneration; Macular degeneration
  • Research Stargardt disease
  • No development reported Degenerative myopia

Most Recent Events

  • 08 Feb 2024 CHA Bio terminates a phase I/IIa trial for Age-related macular degeneration in South Korea due to sponsors decision (NCT01674829)
  • 31 Jul 2023 Early research in Stargardt disease in Japan (Intraocular) (Astellas Pharma pipeline, August 2023)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Degenerative myopia in USA (Intraocular, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top